Videos

Closing out his review of HR+/HER2-low metastatic breast cancer management, Kevin Kalinsky, MD, considers unmet needs and ongoing investigation into novel treatment strategies.

Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic breast cancer and factors that help inform optimal sequencing.

Expert oncologist Kevin Kalinsky, MD, reviews the diagnosis and management of a 65-year old woman with HR+/HER2-low metastatic breast cancer.

Hatem Soliman, MD, explains how to test for HER2 status in patients with breast cancer.

Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Edwin Choy, MD, discusses adjuvant treatments for patients with gastrointestinal stromal tumors.

Richard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.

Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.

Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.

Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.

Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.

Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.

Matthew R. Smith, MD, PhD introduces a nonmetastatic castration-resistant prostate cancer (CRPC) patient case featuring a 52-year-old man referred to urology with a PSA of 6.8 ng/mL.

An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.

An expert hematologist-oncologist discusses the patient case and risk stratification for patients with newly diagnosed CLL.

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

Closing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.

Experts consider how they might approach third-line treatment selection for patients with EGFR exon 20-mutated mNSCLC who experience disease progression on amivantamab or other second-line therapies.

Dr Velázquez Mañana revisits the second patient case and details the use of second-line amivantamab for the patient’s disease progression, and the panel confers about adverse event management strategies for patients taking this regimen.

Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.

Chung-Han Lee, MD, PhD, reviews clinical trial data and how they apply to the evolving treatment landscape in non-clear cell renal cell carcinoma.

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Key opinion leaders in the field of endometrial carcinoma management share advice on optimal patient monitoring and the identification of recurrent disease.

Moving on to discuss the second patient case of ALK+ NSCLC, expert panelists elucidate the sequencing ALK TKIs following progression on first-line therapy.